119 related articles for article (PubMed ID: 2579476)
21. Antibodies to tumor necrosis factor alpha prevent increases in cell replication in liver due to the potent peroxisome proliferator, WY-14,643.
Bojes HK; Germolec DR; Simeonova P; Bruccoleri A; Schoonhoven R; Luster MI; Thurman RG
Carcinogenesis; 1997 Apr; 18(4):669-74. PubMed ID: 9111198
[TBL] [Abstract][Full Text] [Related]
22. Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset.
Lake BG; Evans JG; Gray TJ; Körösi SA; North CJ
Toxicol Appl Pharmacol; 1989 Jun; 99(1):148-60. PubMed ID: 2499080
[TBL] [Abstract][Full Text] [Related]
23. Role of fatty acyl coenzyme A oxidase in the efflux of oxidized glutathione from perfused livers of rats treated with the peroxisome proliferator nafenopin.
Conway JG; Neptun DA; Garvey LK; Popp JA
Cancer Res; 1987 Sep; 47(18):4795-800. PubMed ID: 3621175
[TBL] [Abstract][Full Text] [Related]
24. Assessment of peroxisome proliferation and liver growth-stimulating potential by nondirectly genotoxic compounds in cultured hepatocytes.
Bieri F; Stäubli W; Kelly S; Waechter F; Bentley P
Mol Toxicol; 1987-1988 Fall; 1(4):439-44. PubMed ID: 3151502
[TBL] [Abstract][Full Text] [Related]
25. Lack of evidence for a hepatic peroxisome proliferator receptor and an explanation for the binding of hypolipidaemic drugs to liver homogenates.
Milton MN; Elcombe CR; Kass GE; Gibson GG
Biochem Pharmacol; 1988 Mar; 37(5):793-8. PubMed ID: 3345197
[TBL] [Abstract][Full Text] [Related]
26. Effect of hypolipidemic peroxisome proliferators on unscheduled DNA synthesis in cultured hepatocytes and on mutagenesis in Salmonella.
Glauert HP; Reddy JK; Kennan WS; Sattler GL; Rao VS; Pitot HC
Cancer Lett; 1984 Sep; 24(2):147-56. PubMed ID: 6383598
[TBL] [Abstract][Full Text] [Related]
27. Sequential histologic study of rat liver during peroxisome proliferator [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]-acetic acid (Wy-14,643)-induced carcinogenesis.
Rao MS; Lalwani ND; Reddy JK
J Natl Cancer Inst; 1984 Oct; 73(4):983-90. PubMed ID: 6592391
[TBL] [Abstract][Full Text] [Related]
28. Activation of hypolipidaemic drugs to acyl-coenzyme A thioesters.
Bronfman M; Amigo L; Morales MN
Biochem J; 1986 Nov; 239(3):781-4. PubMed ID: 3827829
[TBL] [Abstract][Full Text] [Related]
29. Saturable binding sites for the coenzyme A ester of nafenopin, a peroxisome proliferator, in rat liver cytosol.
Morgan C; Bronfman M
Xenobiotica; 1995 Dec; 25(12):1293-300. PubMed ID: 8719905
[TBL] [Abstract][Full Text] [Related]
30. Nafenopin, a peroxisome proliferator, depletes hepatic vitamin E content and elevates plasma oxidised glutathione levels in rats.
Lake BG; Gray TJ; Körösi SA; Walters DG
Toxicol Lett; 1989 Feb; 45(2-3):221-9. PubMed ID: 2919403
[TBL] [Abstract][Full Text] [Related]
31. Kupffer cells are causally responsible for the mitogenic effect of peroxisome proliferators.
Rose ML; Germolec DR; Schoonhoven R; Thurman RG
Carcinogenesis; 1997 Aug; 18(8):1453-6. PubMed ID: 9276615
[TBL] [Abstract][Full Text] [Related]
32. Properties of hypolipidemic peroxisome proliferators in the lymphocyte [3H]thymidine and Salmonella mutagenesis assays.
Warren JR; Simmon VF; Reddy JK
Cancer Res; 1980 Jan; 40(1):36-41. PubMed ID: 6765917
[No Abstract] [Full Text] [Related]
33. Stimulation of DNA synthesis but not of peroxisomal beta-oxidation by nafenopin in primary cultures of marmoset hepatocytes.
Bieri F; Stäubli W; Waechter F; Muakkassah-Kelly S; Bentley P
Cell Biol Int Rep; 1988 Dec; 12(12):1077-87. PubMed ID: 3147145
[TBL] [Abstract][Full Text] [Related]
34. Peroxisome proliferator-binding protein: identification and partial characterization of nafenopin-, clofibric acid-, and ciprofibrate-binding proteins from rat liver.
Lalwani ND; Alvares K; Reddy MK; Reddy MN; Parikh I; Reddy JK
Proc Natl Acad Sci U S A; 1987 Aug; 84(15):5242-6. PubMed ID: 3474650
[TBL] [Abstract][Full Text] [Related]
35. Induction of sister chromatid exchange and micronuclei in primary cultures of rat and human hepatocytes by the peroxisome proliferator, Wy-14,643.
Hwang JJ; Hsia MT; Jirtle RL
Mutat Res; 1993 Apr; 286(2):123-33. PubMed ID: 7681523
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of intercellular communication of rat hepatocytes by nafenopin: involvement of protein kinase C.
Leibold E; Greim H; Schwarz LR
Carcinogenesis; 1994 Jun; 15(6):1265-9. PubMed ID: 8020165
[TBL] [Abstract][Full Text] [Related]
37. Effect of peroxisome proliferator carcinogens on unscheduled DNA synthesis in rat hepatocytes determined by autoradiography.
Cattley RC; Richardson KK; Smith-Oliver T; Popp JA; Butterworth BE
Cancer Lett; 1986 Dec; 33(3):269-77. PubMed ID: 3802057
[TBL] [Abstract][Full Text] [Related]
38. Peroxisomal proliferators inhibit acyl CoA synthetase and stimulate protein kinase C in vivo.
Bojes HK; Thurman RG
Toxicol Appl Pharmacol; 1994 Jun; 126(2):233-9. PubMed ID: 8209376
[TBL] [Abstract][Full Text] [Related]
39. Genotoxic effects of selected peroxisome proliferators.
Reisenbichler H; Eckl PM
Mutat Res; 1993 Apr; 286(2):135-44. PubMed ID: 7681524
[TBL] [Abstract][Full Text] [Related]
40. Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse.
Reddy JK; Moody DE; Azarnoff DL; Tomarelli RM
Arch Int Pharmacodyn Ther; 1977 Jan; 225(1):51-7. PubMed ID: 851495
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
